Accelerated Approval For Biomarkers? FDA Considers “Limited Context of Use” To Shorten Qualification Process
This article was originally published in RPM Report
Biomarker qualification is a hot topic for FDA, industry and Congress, based on the premise that better methods to develop and apply novel biomarkers can be the next big step in helping usher in an era of personalized medicine. One common argument is that the current FDA qualification process is too long. FDA is eager to change that perception.
You may also be interested in...
CDER Director Woodcock says agency should write down its definition of a surrogate endpoint, but industry and academics will have to help with requirements for biomarker approval.
FDA’s new drug development qualification process offers a pathway for outside groups to gain acceptance of specific biomarkers for regulatory purposes. FDA recently used the process to qualify a specific biomarker for a severe fungal infection.
US FDA’s 22nd Patient-Focused Drug Development meeting focused on the challenging disease of autism. It also showed how far FDA has come in embracing the patient-input process over the past five years.